0001209191-21-062653.txt : 20211103 0001209191-21-062653.hdr.sgml : 20211103 20211103153012 ACCESSION NUMBER: 0001209191-21-062653 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20211029 FILED AS OF DATE: 20211103 DATE AS OF CHANGE: 20211103 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Willoughby Scott B. CENTRAL INDEX KEY: 0001877368 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-30171 FILM NUMBER: 211375075 MAIL ADDRESS: STREET 1: 7000 MARINA BLVD CITY: BRISBANE STATE: CA ZIP: 94005 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: SANGAMO THERAPEUTICS, INC CENTRAL INDEX KEY: 0001001233 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 680359556 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 7000 MARINA BLVD CITY: BRISBANE STATE: CA ZIP: 94005 BUSINESS PHONE: 5109706000 MAIL ADDRESS: STREET 1: 7000 MARINA BLVD CITY: BRISBANE STATE: CA ZIP: 94005 FORMER COMPANY: FORMER CONFORMED NAME: SANGAMO BIOSCIENCES INC DATE OF NAME CHANGE: 20000208 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2021-10-29 0 0001001233 SANGAMO THERAPEUTICS, INC SGMO 0001877368 Willoughby Scott B. C/O SANGAMO THERAPEUTICS, INC. 7000 MARINA BLVD BRISBANE CA 94005 0 1 0 0 SVP, Gen. Counsel & Secretary Common Stock 2021-10-29 4 F 0 140 8.12 D 54455 D Represents shares underlying the portion of restricted stock unit ("RSU") grant that vested on October 29, 2021 which were surrendered by the Reporting Person to the Issuer for tax withholding, using the Issuer's closing stock price on October 29, 2021 of $8.12/share, pursuant to the terms of the Issuer's Amended and Restated 2018 Equity Incentive Plan, as amended (the "2018 EIP, as amended"). Includes: (a) 265 shares of common stock resulting from the October 29, 2021 vesting of the Reporting Person's November 10, 2020 RSU grant and 405 shares of common stock subject to such RSU grant that will vest in one remaining installment on April 29, 2022; (b) 23,001 shares of common stock issuable upon settlement of RSUs granted to the Reporting Person on April 24, 2020 that will vest in two remaining annual installments on April 24, 2022 and 2023 respectively; (continued in Footnote 3) Continued from Footnote 2 - (c) 13,750 shares of common stock issuable upon settlement of RSUs granted to the Reporting Person on February 25, 2021; and (d) 7,500 shares of common stock subject to RSUs granted to the Reporting Person on August 1, 2021. All such RSUs vest with respect to 1/3rd of the shares granted in three equal annual installments over the three-year period measured from the date of grant, subject to the Reporting Person's Continuous Service (as defined in the Issuer's Amended and Restated 2018 Equity Incentive Plan, as amended), through such dates and subject to acceleration as provided in the 2018 EIP, as amended. /s/ Matthew Colvin, Attorney-in-Fact for Scott B. Willoughby 2021-11-02